Moreover, the 36-month beta value for ARCT is 2.61. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 1 as “sell.”
The public float for ARCT is 24.54M and currently, short sellers hold a 17.14% of that float. On April 05, 2024, ARCT’s average trading volume was 448.22K shares.
ARCT) stock’s latest price update
The stock price of Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has plunged by -6.54 when compared to previous closing price of 32.74, but the company has seen a -6.88% decline in its stock price over the last five trading sessions. Seeking Alpha reported 2024-03-07 that Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Neda Safarzadeh – Vice President, Head of Investor Relations, Public Relations & Marketing. Joe Payne – President & Chief Executive Officer Andy Sassine – Chief Financial Officer Pad Chivukula – Chief Scientific Officer & Chief Operating Officer Conference Call Participants Evan Wang – Guggenheim Securities Whitney Ijem – Canaccord Genuity Myles Minter – William Blair Jan Hughes – Wells Fargo Pete Stavropoulos – Cantor Fitzgerald Thomas Yip – H.C.
ARCT’s Market Performance
Arcturus Therapeutics Holdings Inc (ARCT) has seen a -6.88% fall in stock performance for the week, with a -18.53% decline in the past month and a -2.45% plunge in the past quarter. The volatility ratio for the week is 6.25%, and the volatility levels for the past 30 days are at 6.26% for ARCT. The simple moving average for the last 20 days is -12.28% for ARCT stock, with a simple moving average of 2.78% for the last 200 days.
Analysts’ Opinion of ARCT
Many brokerage firms have already submitted their reports for ARCT stocks, with Canaccord Genuity repeating the rating for ARCT by listing it as a “Buy.” The predicted price for ARCT in the upcoming period, according to Canaccord Genuity is $90 based on the research report published on December 13, 2023 of the previous year 2023.
William Blair, on the other hand, stated in their research note that they expect to see ARCT reach a price target of $71. The rating they have provided for ARCT stocks is “Outperform” according to the report published on July 24th, 2023.
H.C. Wainwright gave a rating of “Buy” to ARCT, setting the target price at $51 in the report published on May 11th of the previous year.
ARCT Trading at -15.17% from the 50-Day Moving Average
After a stumble in the market that brought ARCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.15% of loss for the given period.
Volatility was left at 6.26%, however, over the last 30 days, the volatility rate increased by 6.25%, as shares sank -19.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.64% lower at present.
During the last 5 trading sessions, ARCT fell by -6.88%, which changed the moving average for the period of 200-days by +16.84% in comparison to the 20-day moving average, which settled at $34.52. In addition, Arcturus Therapeutics Holdings Inc saw -2.95% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARCT starting from Chivukula Pad, who sale 17,435 shares at the price of $35.02 back on Mar 25 ’24. After this action, Chivukula Pad now owns 473,448 shares of Arcturus Therapeutics Holdings Inc, valued at $610,574 using the latest closing price.
Chivukula Pad, the Chief Scientific Officer & COO of Arcturus Therapeutics Holdings Inc, sale 8,565 shares at $35.01 during a trade that took place back on Mar 19 ’24, which means that Chivukula Pad is holding 490,883 shares at $299,839 based on the most recent closing price.
Stock Fundamentals for ARCT
Current profitability levels for the company are sitting at:
- -0.44 for the present operating margin
- 0.34 for the gross margin
The net margin for Arcturus Therapeutics Holdings Inc stands at -0.17. The total capital return value is set at -0.2. Equity return is now at value -9.69, with -6.04 for asset returns.
Based on Arcturus Therapeutics Holdings Inc (ARCT), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -0.6. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is -92.63.
Currently, EBITDA for the company is -1.2 million with net debt to EBITDA at 3.17. When we switch over and look at the enterprise to sales, we see a ratio of 3.15. The receivables turnover for the company is 5.02for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.72.
Conclusion
To wrap up, the performance of Arcturus Therapeutics Holdings Inc (ARCT) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
